Condition: IBD · Crohn Disease · Ulcerative Colitis (UC) · Sponsor: Assistance Publique - Hôpitaux de Paris
Inflammatory Bowel Disease (IBD) often leads to poor disease control and reduced quality of life. Changes in the gut microbiota may disrupt the energy metabolism of immune cells, contributing to IBD. This study will examine how gut microbiota affects immune cell metabolism in healthy adults and IBD patients. Healthy volunteers will be tested before and after a short antibiotic treatment, while IBD patients will be tested once. Energy metabolism will be measured using SCENITH, a method that analyzes metabolic activity in blood immune cells. Participants will also receive a special form of fiber (13C-labeled inulin) to track how gut bacteria break down and use this nutrient. Blood, urine, and stool samples will be analyzed to follow the metabolic fate of inulin. DNA and RNA from stool will be studied to identify which bacteria metabolize the labeled fiber.
This description comes directly from the study's public registry record.
Harry SOKOL, PU-PH · 00 33 1 49 28 31 62 · harry.sokol@aphp.fr
Mélissa MONTIL, Praticien attaché · 00 33 1 71 97 0810 · melissa.montil@aphp.fr
Always discuss trial participation with your own doctor first.
| Gastroenterology Department Saint Antoine Hospital, | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07300553